EGFR and non-small cell lung carcinoma: A study by Osude et al. demonstrated that in EGFR-TKI-resistant NSCLC cell lines—specifically those harboring EGFR double mutations (L858R and T790M)—the expression of VEGF, VEGFR-2, and its co-receptor neuropilin-1 (NP-1) was significantly more elevated than that in parental or single-mutant cells.